

**Companion Animal Pharmaceuticals Market by Animal Type (Dogs, Cats, Horses),
Route of Administration (Oral, Injectable, Topical), Indication (Antibiotics,
Parasiticides), Distribution Channel (Veterinary Hospitals & Clinics) & Region - Global
Forecasts to 2027**

Market Report | 2023-03-22 | 268 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global companion animal pharmaceuticals market is projected to reach USD 19.6 billion by 2027 from USD 14.4 billion in 2022, at a CAGR of 6.3% during the forecast period. The Rising prevalence of zoonotic diseases, Rising demand for pet insurance due to growing animal health expenditure, Increasing R&D investments for animal healthcare, Initiatives by various government agencies and animal associations, High pet ownership rates worldwide are some of the factors driving the growth of these markets. However, Rising pet care costs, Limited number of new product developments, High cost of vaccines and complexities associated with storage, Growing resistance to antimicrobials and antibiotics are restraining the growth of this market to a certain extent.

"The dermatologic diseases segment is projected to grow at the highest CAGR in the companion animal pharmaceuticals market." The dermatologic diseases segment is projected to grow at the highest CAGR during the forecast period. The rising need for advanced orthopedic drugs, increasing prevalence of arthritis, and growing pet population in developed and developing countries are some of the key factors driving the growth of this segment.

"In the forecast period, the dogs segment holds the largest share in the animal type segment." The dogs segment accounted for the largest market share in 2021. The large share of this segment is attributed to the increasing dog population and rising ownership rate in both developed and developing countries, rising canine healthcare expenditure, increasing prevalence of zoonotic diseases and other skin allergies in dogs, and the rising number of pet insurers across the globe.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

"In the forecast period, by distribution channel segment, veterinary hospitals is expected to grow at the highest CAGR in the companion animal pharmaceuticals market"

During the forecast period, the veterinary hospitals segment is expected to grow at the highest CAGR. The higher adoption of animal parasiticides, analgesic, antimicrobials and antibiotics in hospital settings, rising cases of infectious diseases, increasing number of veterinary hospitals, growing ownership rate of companion animals, and rising veterinary expenditure are some of the key factors driving the growth of this segment.

"By Region, North America holds the largest share in the companion animal pharmaceuticals market, in the forecast period"

By Region, In 2021, North America accounted for the largest share of the companion animal pharmaceuticals market in the forecast period, followed by Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The large share of North America can be attributed to the high adoption rate of companion animals such as dogs and cats, well-established base of animal health industries, rising animal adoption centers, rising cases of parasitic infections, the large number of hospitals and clinics, growing expenditure on animal health in the region and , growing pool of veterinarians.

A breakdown of the primary participants for the companion animal pharmaceuticals market referred to for this report is provided below:

-□By Company Type: Tier 1-35%, Tier 2-45%, and Tier 3-20%

-□By Designation: C-level-35%, Director Level-25%, and Others-40%

-□By Region: North America-40%, Asia- Pacific-30%, Europe-20%, Middle East & Africa-5%, Latin America- 5%

The prominent players in the global companion animal pharmaceuticals market are Zoetis, Inc. (US), Merck & Co., Inc. (US), Boehringer Ingelheim International GmbH (Germany), Elanco Animal Health Incorporated (US), Eco Animal Health Group PIC (UK), Virbac (France), Dechra Pharmaceuticals PLC (UK), Vetoquinol (France), Neogen Corporation (US), Orion Group (Finland), Zenex Animal Health India Private Limited (India), Norbrook Holdings Limited (UK), Chanelle Pharma (Ireland), HIPRA (Spain), Ceva Sante Animale (France), Tianjin Ringpu Bio-Technology Co Ltd. (China), Kyoritsu Seiyaku (Japan), Endovac Animal Health (US), Indian Immunologicals Ltd (India), Ashish Life Sciences Pvt Ltd (India), Lutim Pharma Pvt Ltd (India), Biogenesis Bago (US), Brilliant Bio Pharma (India), Intas Pharmaceuticals (India), and Vetindia Pharmaceuticals limited (India).

Research Coverage:

This research report categorizes the companion animal pharmaceuticals market by indication, by route of administration, by animal type, by distribution channel and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the companion animal pharmaceuticals market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements. new product & service launches, mergers and acquisitions, and recent developments associated with the companion animal pharmaceuticals market. Competitive analysis of upcoming startups in the C4ISR market ecosystem is covered in this report.

Reasons to Buy the Report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall C4ISR market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report provides insights on the following pointers:

-□Market Penetration: Comprehensive information on the product portfolios offered by the top players in the global companion animal pharmaceuticals market

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product or service launches in the global companion animal pharmaceuticals market
- Market Development: Comprehensive information on the lucrative emerging regions by indication, animal type, distribution channels, and region
- Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global companion animal pharmaceuticals market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and products of leading players in the global companion animal pharmaceuticals market

Table of Contents:

1□INTRODUCTION□	31
1.1□STUDY OBJECTIVES□	31
1.2□MARKET DEFINITION□	31
1.2.1□INCLUSIONS AND EXCLUSIONS□	32
1.2.2□MARKETS COVERED□	33
FIGURE 1□COMPANION ANIMAL PHARMACEUTICALS MARKET SEGMENTATION□	33
1.2.3□YEARS CONSIDERED□	33
1.3□CURRENCY CONSIDERED□	34
TABLE 1□EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD□	34
1.4□LIMITATIONS□	34
1.5□STAKEHOLDERS□	34
1.6□SUMMARY OF CHANGES□	35
1.6.1□REFINEMENTS IN SEGMENTS OF GLOBAL MARKET□	35
1.6.2□UPDATED FINANCIAL INFORMATION/PRODUCT PORTFOLIOS OF PLAYERS□	35
1.6.3□UPDATED MARKET DEVELOPMENTS OF PROFILED PLAYERS□	35
1.6.4□ADDITION OF RECESSION IMPACT□	35
2□RESEARCH METHODOLOGY□	36
2.1□RESEARCH APPROACH□	36
FIGURE 2□RESEARCH DESIGN□	36
2.1.1□SECONDARY RESEARCH□	37
2.1.1.1□Key data from secondary sources□	38
2.1.2□PRIMARY RESEARCH□	38
2.1.2.1□Primary sources□	39
2.1.2.2□Key data from primary sources□	40
2.1.2.3□Key industry insights□	41
2.1.2.4□Breakdown of primaries□	42
FIGURE 3□BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION□	42
2.2□MARKET SIZE ESTIMATION□	42
FIGURE 4□MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS□	43
FIGURE 5□REVENUE SHARE ANALYSIS ILLUSTRATION: ZOETIS INC.□	43
FIGURE 6□COMPANION ANIMAL PHARMACEUTICALS MARKET: SUPPLY-SIDE ANALYSIS□	44
FIGURE 7□MARKET ANALYSIS APPROACH□	45
FIGURE 8□EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET APPROACH□	45
FIGURE 9□TOP-DOWN APPROACH□	46
FIGURE 10□CAGR PROJECTIONS□	47
FIGURE 11□COMPANION ANIMAL PHARMACEUTICALS MARKET (2022-2027): IMPACT ANALYSIS ON DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES□	48

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.3	DATA TRIANGULATION APPROACH	50
FIGURE 12	DATA TRIANGULATION METHODOLOGY	50
2.4	MARKET SHARE ESTIMATION	51
2.5	STUDY ASSUMPTIONS	51
2.6	RISK ASSESSMENT	52
2.7	LIMITATIONS	52
2.7.1	METHODOLOGY-RELATED LIMITATIONS	52
2.7.2	SCOPE-RELATED LIMITATIONS	52
2.8	IMPACT OF RECESSION	52
3	EXECUTIVE SUMMARY	53
FIGURE 13	COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2022 VS. 2027 (USD MILLION)	53
FIGURE 14	COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2022 VS. 2027 (USD MILLION)	54
FIGURE 15	COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2022 VS. 2027 (USD MILLION)	54
FIGURE 16	COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2022 VS. 2027 (USD MILLION)	55
FIGURE 17	COMPANION ANIMAL PHARMACEUTICALS MARKET: GEOGRAPHICAL SNAPSHOT	56
4	PREMIUM INSIGHTS	57
4.1	COMPANION ANIMAL PHARMACEUTICALS MARKET OVERVIEW	57
FIGURE 18	INCREASING PREVALENCE OF ZOO NOTIC DISEASES AND RISING PET OWNERSHIP RATES WORLDWIDE TO DRIVE MARKET	57
4.2	EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION AND COUNTRY (2021)	58
FIGURE 19	INFECTIOUS DISEASES SEGMENT IN GERMANY ACCOUNTED FOR LARGEST SHARE IN 2021	58
4.3	COMPANION ANIMAL PHARMACEUTICALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	59
FIGURE 20	CHINA & INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD	59
4.4	COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION (2022-2027)	60
FIGURE 21	ASIA PACIFIC TO WITNESS HIGHEST CAGR DURING FORECAST PERIOD	60
4.5	COMPANION ANIMAL PHARMACEUTICALS MARKET: DEVELOPED VS. EMERGING MARKETS	60
FIGURE 22	EMERGING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD	60
?		
5	MARKET OVERVIEW	61
5.1	INTRODUCTION	61
5.2	MARKET DYNAMICS	62
FIGURE 23	COMPANION ANIMAL PHARMACEUTICALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	62
5.2.1	MARKET DRIVERS	62
5.2.1.1	Rising prevalence of zoonotic diseases	62
TABLE 2	ANIMAL DISEASE OUTBREAKS IN ASIA PACIFIC COUNTRIES (2013-2019)	63
5.2.1.2	Rising demand for pet insurance due to growing animal health expenditure	64
TABLE 3	US: AVERAGE PREMIUM RATES (2019-2021)	64
FIGURE 24	CANADA: AVERAGE ANNUAL PREMIUMS (2017-2021)	64
TABLE 4	NORTH AMERICA: PET HEALTH INSURANCE MARKET, 2012-2021 (USD MILLION)	65
5.2.1.3	Increasing R&D investments for animal healthcare	65
5.2.1.4	Rising awareness initiatives by government agencies and animal welfare organizations	66
5.2.1.5	High pet ownership rates worldwide	67
TABLE 5	PET POPULATION, BY ANIMAL, 2014-2020 (MILLION)	67
TABLE 6	MARKET DRIVERS: IMPACT ANALYSIS	68
5.2.2	MARKET RESTRAINTS	68
5.2.2.1	Rising pet care costs	68
FIGURE 25	US: PET INDUSTRY EXPENDITURE, 2010-2020	69

5.2.2.2	Limited number of novel pharmaceuticals for veterinary care	69
5.2.2.3	High cost of vaccines and complexities associated with storage	69
5.2.2.4	Growing resistance to antimicrobials and antibiotics	70
TABLE 7 MARKET RESTRAINTS: IMPACT ANALYSIS		
5.2.3	MARKET OPPORTUNITIES	71
5.2.3.1	Lucrative growth opportunities in emerging markets	71
5.2.3.2	Growing prevalence of chronic animal diseases	72
5.2.3.3	Rising technological advancements in vaccine manufacturing	72
TABLE 8 MARKET OPPORTUNITIES: IMPACT ANALYSIS		
5.2.4	MARKET CHALLENGES	73
5.2.4.1	Stringent regulatory approval process for pharmaceuticals	73
5.2.4.2	Limited awareness of vaccine coverage	73
5.2.4.3	Misdiagnosis due to diversity of parasites	74
5.2.4.4	Low animal healthcare expenditure in emerging markets	74
TABLE 9 MARKET CHALLENGES: IMPACT ANALYSIS		
?		
6	INDUSTRY INSIGHTS	75
6.1	INTRODUCTION	75
6.2	INDUSTRY TRENDS	75
6.2.1	RISING ACQUISITIONS OF SMALLER COMPANIES BY GLOBAL PLAYERS	75
TABLE 10 COMPANION ANIMAL PHARMACEUTICALS MARKET: MAJOR ACQUISITIONS (2017-2022)		
6.2.2	INCREASING PRODUCT INNOVATIONS FOR ANIMAL HEALTHCARE	76
TABLE 11 INNOVATIVE COMPANION ANIMAL PHARMACEUTICAL TRENDS		
6.2.3	EXPANDING VETERINARY BUSINESSES WORLDWIDE	77
6.3	PORTER'S FIVE FORCES ANALYSIS	78
TABLE 12 PORTER'S FIVE FORCES ANALYSIS		
6.3.1	THREAT OF NEW ENTRANTS	78
6.3.2	THREAT OF SUBSTITUTES	79
6.3.3	BARGAINING POWER OF SUPPLIERS	79
6.3.4	BARGAINING POWER OF BUYERS	79
6.3.5	INTENSITY OF COMPETITIVE RIVALRY	79
6.4	REGULATORY ANALYSIS	80
FIGURE 26 COMPANION ANIMAL PHARMACEUTICAL MARKET: DEVELOPMENT AND APPROVAL PROCESS FOR PRODUCTS		
TABLE 13 US: RECENT DEVELOPMENTS IN REGULATIONS FOR VETERINARY DRUGS		
FIGURE 27 COMPANION ANIMAL PHARMACEUTICAL MARKET: PRODUCT APPROVAL PROCESS IN EUROPE		
6.4.1	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	84
6.4.1.1	US	84
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS		
6.4.1.2	Europe	86
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS		
6.4.1.3	Rest of the World	87
TABLE 16 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS		
6.5	VALUE CHAIN ANALYSIS	87
FIGURE 28 COMPANION ANIMAL PHARMACEUTICALS MARKET: VALUE CHAIN ANALYSIS		
6.6	SUPPLY CHAIN ANALYSIS	88
FIGURE 29 COMPANION ANIMAL PHARMACEUTICALS MARKET: SUPPLY CHAIN ANALYSIS		
6.7	ECOSYSTEM ANALYSIS	90

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6.7.1	COMPANION ANIMAL PHARMACEUTICALS MARKET: ECOSYSTEM ANALYSIS	90
FIGURE 30	COMPANION ANIMAL PHARMACEUTICALS MARKET: ECOSYSTEM ANALYSIS	91
6.8	PATENT ANALYSIS	91
6.8.1	COMPANION ANIMAL PHARMACEUTICALS MARKET: PATENT ANALYSIS TRENDS	91
FIGURE 31	PATENT PUBLICATION TRENDS (JANUARY 2013-DECEMBER 2022)	91
6.8.2	TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR COMPANION ANIMAL PHARMACEUTICALS	92
FIGURE 32	COMPANION ANIMAL PHARMACEUTICALS MARKET: TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR PATENTS (2017-2022)	92
6.8.3	JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR COMPANION ANIMAL PHARMACEUTICALS	93
FIGURE 33	COMPANION ANIMAL PHARMACEUTICAL MARKET: TOP APPLICANT COUNTRIES FOR PATENTS (2017-2022)	93
6.9	PRICING ANALYSIS	93
TABLE 17	AVERAGE SELLING PRICES OF COMPANION ANIMAL PHARMACEUTICALS BY APPLICATION (USD)	93
6.10	KEY CONFERENCES AND EVENTS FROM 2023 TO 2024	94
TABLE 18	COMPANION ANIMAL PHARMACEUTICALS MARKET: CONFERENCES AND EVENTS	94
6.11	KEY STAKEHOLDERS & BUYING CRITERIA	95
6.11.1	KEY STAKEHOLDERS IN BUYING PROCESS	95
FIGURE 34	INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 APPLICATIONS	95
TABLE 19	INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 APPLICATIONS	95
FIGURE 35	BUYING CRITERIA	96
TABLE 20	KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS	96
6.12	TRADE ANALYSIS	96
7	COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION	97
7.1	INTRODUCTION	98
TABLE 21	COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020-2027 (USD MILLION)	98
7.2	INFECTIOUS DISEASES	98
TABLE 22	COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020-2027 (USD MILLION)	99
TABLE 23	COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)	99
7.2.1	PARASITICIDES	100
7.2.1.1	Growing regulatory guidelines to control parasite-related diseases to fuel market	100
TABLE 24	COMPANION ANIMAL PHARMACEUTICALS MARKET FOR PARASITICIDES, BY COUNTRY, 2020-2027 (USD MILLION)	101
7.2.2	VACCINES	101
7.2.2.1	Growing awareness among pet owners for canine & feline vaccines to drive market	101
TABLE 25	COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VACCINES, BY COUNTRY, 2020-2027 (USD MILLION)	103
7.2.3	ANTIBIOTICS AND ANTIMICROBIALS	103
7.2.3.1	Effective prevention for clinical and subclinical diseases in companion animals to fuel uptake	103
TABLE 26	COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ANTIBIOTICS AND ANTIMICROBIALS, BY COUNTRY, 2020-2027 (USD MILLION)	104
7.2.4	OTHERS	105
TABLE 27	COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHERS, BY COUNTRY, 2020-2027 (USD MILLION)	106
7.3	DERMATOLOGIC DISEASES	106
7.3.1	RIISING CASES OF DERMATITIS DUE TO NUTRITIONAL DEFICIENCIES TO DRIVE MARKET	106
TABLE 28	COMPANION ANIMAL PHARMACEUTICALS MARKET FOR DERMATOLOGIC DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)	107
7.4	PAIN	108
7.4.1	RIISING DEMAND FOR ANTI-INFLAMMATORY DRUGS AND OPIOIDS TO DRIVE MARKET	108
TABLE 29	COMPANION ANIMAL PHARMACEUTICALS MARKET FOR PAIN, BY COUNTRY, 2020-2027 (USD MILLION)	109
7.5	ORTHOPEDIC DISEASES	109

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

7.5.1	GROWING PREVALENCE OF OSTEOARTHRITIS DUE TO INCREASING OBESITY IN PETS TO DRIVE MARKET	109
TABLE 30 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)		
7.6	BEHAVIORAL DISORDERS	110
7.6.1	INCREASING AWARENESS AMONG PET OWNERS FOR APPROPRIATE PET BEHAVIOR TO SUPPORT MARKET GROWTH	110
TABLE 31 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR BEHAVIORAL DISORDERS, BY COUNTRY, 2020-2027 (USD MILLION)		
7.7	OTHER INDICATIONS	112
TABLE 32 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)		
8 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION		
8.1	INTRODUCTION	115
TABLE 33 ROUTES OF ADMINISTRATION FOR KEY COMPANION ANIMAL PHARMACEUTICALS		
TABLE 34 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)		
8.2	ORAL ADMINISTRATION	116
8.2.1	ABILITY TO TREAT A WIDE RANGE OF DISEASES AND AFFORDABILITY OF MEDICATION TO DRIVE DEMAND	116
TABLE 35 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2020-2027 (USD MILLION)		
8.3	INJECTABLE ADMINISTRATION	117
8.3.1	ADVANTAGES OF COMPLETE ABSORPTION AND BIOAVAILABILITY TO FUEL MARKET	117
TABLE 36 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INJECTABLE ADMINISTRATION, BY COUNTRY, 2020-2027 (USD MILLION)		
?		
8.4	TOPICAL ADMINISTRATION	118
8.4.1	TEMPORARY EFFECTS OF TOPICAL DRUGS COMPARED TO ORAL AND PARENTERAL DRUGS TO RESTRAIN MARKET	118
TABLE 37 COMPANION ANIMAL PHARMACEUTICAL MARKET FOR TOPICAL ADMINISTRATION, BY COUNTRY, 2020-2027 (USD MILLION)		
9 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE		
9.1	INTRODUCTION	121
TABLE 38 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020-2027 (USD MILLION)		
9.2	DOGS	121
9.2.1	RISING PET DOG POPULATION WORLDWIDE TO DRIVE MARKET	121
FIGURE 36 GROWING PET DOG POPULATION IN INDIA (MILLION)		
FIGURE 37 POPULATION OF PET DOGS GLOBALLY (MILLION)		
TABLE 39 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR DOGS, BY COUNTRY, 2020-2027 (USD MILLION)		
9.3	CATS	124
9.3.1	INCREASING R&D ACTIVITIES ON FELINE HEALTH TO DRIVE MARKET	124
TABLE 40 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR CATS, BY COUNTRY, 2020-2027 (USD MILLION)		
9.4	HORSES	125
9.4.1	RISING PREVALENCE OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH	125
TABLE 41 HORSE POPULATION, BY REGION, 2016-2020 (MILLION)		
TABLE 42 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR HORSES, BY COUNTRY, 2020-2027 (USD MILLION)		
9.5	OTHER COMPANION ANIMALS	127
TABLE 43 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHER COMPANION ANIMALS, BY COUNTRY, 2020-2027 (USD MILLION)		
10 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL		
10.1	INTRODUCTION	130
TABLE 44 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)		

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.2	VETERINARY HOSPITALS	130
10.2.1	GROWING FOCUS ON HEALTHCARE AND COMPANION ANIMAL DIAGNOSTIC SERVICES TO DRIVE MARKET	130
TABLE 45	VETERINARY VISIT EXPENSES FOR CATS AND DOGS (US)	131
TABLE 46	COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VETERINARY HOSPITALS, BY COUNTRY, 2020-2027 (USD MILLION)	131
10.3	VETERINARY CLINICS	132
10.3.1	RIISING NUMBER OF PRIVATE CLINICAL PRACTICES TO DRIVE MARKET	132
TABLE 47	NUMBER OF PRIVATE CLINICAL PRACTICES, BY COUNTRY (2019 VS. 2021)	132
TABLE 48	COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VETERINARY CLINICS, BY COUNTRY, 2020-2027 (USD MILLION)	133
10.4	RETAIL PHARMACIES	134
10.4.1	ACCESSIBILITY OF PHARMACEUTICALS THROUGH PRESCRIPTIONS AND OTC MEDICATION TO SUPPORT MARKET GROWTH	134
TABLE 49	COMPANION ANIMAL PHARMACEUTICALS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2020-2027 (USD MILLION)	135
11	COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION	136
11.1	INTRODUCTION	137
TABLE 50	COMPANION ANIMAL POPULATION, BY COUNTRY, 2022 (THOUSAND)	137
FIGURE 38	COMPANION ANIMAL PHARMACEUTICALS MARKET: GEOGRAPHIC SNAPSHOT	138
TABLE 51	COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION, 2020-2027 (USD MILLION)	138
11.2	NORTH AMERICA	139
FIGURE 39	EXPECTED GROWTH FOR NUMBER OF VETERINARIANS IN NORTH AMERICA (2012 VS. 2030)	140
11.2.1	NORTH AMERICA: RECESSION IMPACT	140
FIGURE 40	NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET SNAPSHOT	141
TABLE 52	NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)	141
TABLE 53	NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020-2027 (USD MILLION)	142
TABLE 54	NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020-2027 (USD MILLION)	142
TABLE 55	NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)	142
TABLE 56	NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020-2027 (USD MILLION)	143
TABLE 57	NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)	143
11.2.2	US	143
11.2.2.1	Rising pet expenditure to fuel market	143
FIGURE 41	US: POPULATION OF DOGS, 2012-2020 (MILLION)	144
FIGURE 42	US: EXPENDITURE ON VET VISITS, 2013-2020	144
TABLE 58	US: PRIVATE CLINICAL PRACTICES, BY ANIMAL TYPE, 2019-2021	144
TABLE 59	US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020-2027 (USD MILLION)	145
TABLE 60	US: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020-2027 (USD MILLION)	145
TABLE 61	US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)	145
TABLE 62	US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020-2027 (USD MILLION)	146
TABLE 63	US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)	146
11.2.3	CANADA	146
11.2.3.1	Increasing pet ownership rates to drive demand for vaccines	146
TABLE 64	CANADA: COMPANION ANIMAL POPULATION, 2016-2020 (MILLION)	147
TABLE 65	CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020-2027 (USD MILLION)	147
TABLE 66	CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020-2027 (USD MILLION)	147

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 67	CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)	148
TABLE 68	CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020-2027 (USD MILLION)	148
TABLE 69	CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)	148
11.3	EUROPE	149
TABLE 70	EUROPE: COMPANION ANIMAL POPULATION, 2021 (MILLION)	149
TABLE 71	EUROPE: NUMBER OF VETERINARIANS, 2014-2020	150
11.3.1	EUROPE: RECESSION IMPACT	150
TABLE 72	EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)	150
TABLE 73	EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020-2027 (USD MILLION)	151
TABLE 74	EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020-2027 (USD MILLION)	151
TABLE 75	EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)	151
TABLE 76	EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020-2027 (USD MILLION)	152
TABLE 77	EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)	152
11.3.2	GERMANY	152
11.3.2.1	Rising focus on animal health due to increasing vet practices to drive market	152
TABLE 78	GERMANY: COMPANION ANIMAL POPULATION, 2016-2021 (MILLION)	153
TABLE 79	GERMANY: NUMBER OF VETERINARIANS, 2015 VS. 2020	153
TABLE 80	GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020-2027 (USD MILLION)	153
TABLE 81	GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020-2027 (USD MILLION)	154
TABLE 82	GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)	154
TABLE 83	GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020-2027 (USD MILLION)	154
TABLE 84	GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)	155
?		
11.3.3	UK	155
11.3.3.1	Availability of animal health insurance policies to fuel market for pharmaceuticals	155
TABLE 85	UK: COMPANION ANIMAL POPULATION, 2017-2020 (MILLION)	155
TABLE 86	UK: NUMBER OF VETERINARIANS, 2016 VS. 2020	156
TABLE 87	UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020-2027 (USD MILLION)	156
TABLE 88	UK: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020-2027 (USD MILLION)	156
TABLE 89	UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)	157
TABLE 90	UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020-2027 (USD MILLION)	157
TABLE 91	UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)	157
11.3.4	FRANCE	158
11.3.4.1	Rising prevalence of infectious diseases to drive demand for animal health products	158
TABLE 92	FRANCE: COMPANION ANIMAL POPULATION, 2010-2021 (MILLION)	158
TABLE 93	FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020-2027 (USD MILLION)	159
TABLE 94	FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020-2027 (USD MILLION)	159
TABLE 95	FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)	159
TABLE 96	FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020-2027 (USD MILLION)	160

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 97	FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)	160
11.3.5	SPAIN	160
11.3.5.1	Increasing adoption rates of dogs and cats to fuel market	160
TABLE 98	SPAIN: COMPANION ANIMAL POPULATION, 2016-2021 (MILLION)	161
TABLE 99	SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020-2027 (USD MILLION)	161
TABLE 100	SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020-2027 (USD MILLION)	161
TABLE 101	SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)	162
TABLE 102	SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020-2027 (USD MILLION)	162
TABLE 103	SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)	162
11.3.6	ITALY	163
11.3.6.1	Lucrative animal and pet health sectors to drive market growth	163
TABLE 104	ITALY: PET POPULATION, 2017-2021 (MILLION)	163
TABLE 105	ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020-2027 (USD MILLION)	163
TABLE 106	ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020-2027 (USD MILLION)	164
TABLE 107	ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)	164
TABLE 108	ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020-2027 (USD MILLION)	164
TABLE 109	ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)	165
11.3.7	REST OF EUROPE	165
TABLE 110	REST OF EUROPE: COMPANION ANIMAL OWNERSHIP, 2018 (MILLION)	165
TABLE 111	REST OF EUROPE: NUMBER OF VETERINARIANS AND PARAVETERINARIANS, 2019 VS. 2020	166
TABLE 112	REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020-2027 (USD MILLION)	166
TABLE 113	REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020-2027 (USD MILLION)	167
TABLE 114	REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)	167
TABLE 115	REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020-2027 (USD MILLION)	167
TABLE 116	REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)	168
11.4	ASIA PACIFIC	168
11.4.1	ASIA PACIFIC: RECESSION IMPACT	168
FIGURE 43	ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET SNAPSHOT	169
TABLE 117	ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)	170
TABLE 118	ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020-2027 (USD MILLION)	170
TABLE 119	ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020-2027 (USD MILLION)	170
TABLE 120	ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)	171
TABLE 121	ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020-2027 (USD MILLION)	171
TABLE 122	ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)	171
11.4.2	CHINA	172
11.4.2.1	Rising number of zoonotic & infectious diseases in animals to drive market	172
FIGURE 44	CHINA: PROJECTED COMPANION ANIMAL POPULATION, 2018-2025 (MILLION)	173

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 123	CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020-2027 (USD MILLION)	173
TABLE 124	CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020-2027 (USD MILLION)	174
TABLE 125	CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)	174
TABLE 126	CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020-2027 (USD MILLION)	174
TABLE 127	CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)	175
11.4.3	JAPAN	175
11.4.3.1	Rising demand for imported breeds to support market growth	175
TABLE 128	JAPAN: DOMESTICATED DOG AND CAT POPULATION, 2012-2020 (THOUSAND)	175
TABLE 129	JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020-2027 (USD MILLION)	176
TABLE 130	JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020-2027 (USD MILLION)	176
TABLE 131	JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)	176
TABLE 132	JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020-2027 (USD MILLION)	177
TABLE 133	JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)	177
11.4.4	INDIA	177
11.4.4.1	Rising focus on pet care due to a large population of domesticated animals to drive market	177
FIGURE 45	INDIA: PROJECTED COMPANION ANIMAL POPULATION, 2018-2025 (MILLION)	178
TABLE 134	INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020-2027 (USD MILLION)	178
TABLE 135	INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020-2027 (USD MILLION)	179
TABLE 136	INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)	179
TABLE 137	INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020-2027 (USD MILLION)	179
TABLE 138	INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)	180
11.4.5	SOUTH KOREA	180
11.4.5.1	Pet care initiatives for street dogs and cats to fuel market for animal care products	180
TABLE 139	SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020-2027 (USD MILLION)	181
TABLE 140	SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020-2027 (USD MILLION)	181
TABLE 141	SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)	181
TABLE 142	SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020-2027 (USD MILLION)	182
TABLE 143	SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)	182
?		
11.4.6	AUSTRALIA	182
11.4.6.1	Growing awareness of parasitic infections to drive demand for parasiticides	182
FIGURE 46	AUSTRALIA: PROJECTED COMPANION ANIMAL POPULATION, 2018-2025 (MILLION)	183
TABLE 144	AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020-2027 (USD MILLION)	183
TABLE 145	AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020-2027 (USD MILLION)	184
TABLE 146	AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)	184
TABLE 147	AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020-2027 (USD MILLION)	184

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 148	AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)	185
11.4.7	REST OF ASIA PACIFIC	185
TABLE 149	REST OF ASIA PACIFIC: NUMBER OF VETERINARIANS, 2012-2021	185
TABLE 150	REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020-2027 (USD MILLION)	186
TABLE 151	REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020-2027 (USD MILLION)	186
TABLE 152	REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)	186
TABLE 153	REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020-2027 (USD MILLION)	187
TABLE 154	REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)	187
11.5	LATIN AMERICA	187
11.5.1	GROWING POOL OF SKILLED VETERINARIANS OWING TO RISING PET POPULATION TO DRIVE MARKET	187
TABLE 155	NUMBER OF VETERINARIANS AND VETERINARY PARA-PROFESSIONALS IN LATIN AMERICA (2016 VS. 2019)	188
11.5.2	LATIN AMERICA: RECESSION IMPACT	188
TABLE 156	LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020-2027 (USD MILLION)	189
TABLE 157	LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020-2027 (USD MILLION)	189
TABLE 158	LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)	189
TABLE 159	LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020-2027 (USD MILLION)	190
TABLE 160	LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)	190
11.6	MIDDLE EAST & AFRICA	190
11.6.1	EMERGING MARKET FOR ANIMAL HEALTHCARE PRACTISES TO SUPPORT UPTAKE	190
11.6.2	MIDDLE EAST & AFRICA: RECESSION IMPACT	191
TABLE 161	MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020-2027 (USD MILLION)	191
TABLE 162	MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020-2027 (USD MILLION)	192
TABLE 163	MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)	192
TABLE 164	MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020-2027 (USD MILLION)	192
TABLE 165	MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)	193
12	COMPETITIVE LANDSCAPE	194
12.1	OVERVIEW	194
FIGURE 47	KEY PLAYER STRATEGIES ADOPTED BY MARKET PLAYERS (2019-2022)	195
12.2	REVENUE SHARE ANALYSIS OF TOP FIVE PLAYERS	195
FIGURE 48	COMPANION ANIMAL PHARMACEUTICALS MARKET: REVENUE SHARE ANALYSIS OF TOP FIVE PLAYERS (2017-2021)	196
12.3	MARKET SHARE ANALYSIS	196
FIGURE 49	COMPANION ANIMAL PHARMACEUTICALS MARKET SHARE, BY KEY PLAYER (2021)	197
12.4	COMPANY EVALUATION QUADRANT	198

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.4.1 STARS198

12.4.2 EMERGING LEADERS199

12.4.3 PERVASIVE PLAYERS199

12.4.4 PARTICIPANTS199

FIGURE 50 COMPANION ANIMAL PHARMACEUTICALS MARKET: COMPANY EVALUATION QUADRANT (2021)200

12.5 EVALUATION QUADRANT FOR STARTUPS/SMES200

12.5.1 PROGRESSIVE COMPANIES200

12.5.2 DYNAMIC COMPANIES201

12.5.3 STARTING BLOCKS201

12.5.4 RESPONSIVE COMPANIES201

FIGURE 51 COMPANION ANIMAL PHARMACEUTICALS MARKET: STARTUPS/SME EVALUATION QUADRANT (2021)201

12.6 COMPETITIVE BENCHMARKING202

TABLE 166 COMPANION ANIMAL PHARMACEUTICALS MARKET: INDICATION PORTFOLIO ANALYSIS:202

TABLE 167 COMPANION ANIMAL PHARMACEUTICALS MARKET: ROUTE OF ADMINISTRATION PORTFOLIO ANALYSIS203

TABLE 168 COMPANION ANIMAL PHARMACEUTICALS MARKET: ANIMAL TYPE PORTFOLIO ANALYSIS205

TABLE 169 COMPANION ANIMAL PHARMACEUTICALS MARKET: DISTRIBUTION CHANNEL PORTFOLIO ANALYSIS206

12.7 COMPANY GEOGRAPHIC FOOTPRINT207

TABLE 170 COMPANION ANIMAL PHARMACEUTICALS MARKET: REGIONAL REVENUE MIX207

?

12.8 COMPETITIVE SITUATION AND TRENDS208

12.8.1 PRODUCT LAUNCHES & APPROVALS208

TABLE 171 PRODUCT LAUNCHES & APPROVALS208

12.8.2 DEALS210

TABLE 172 DEALS210

12.8.3 OTHER DEVELOPMENTS213

TABLE 173 OTHER DEVELOPMENTS213

13 COMPANY PROFILES214

(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*

13.1 KEY PLAYERS214

13.1.1 ZOETIS INC.214

TABLE 174 ZOETIS INC.: BUSINESS OVERVIEW214

FIGURE 52 ZOETIS: COMPANY SNAPSHOT (2021)215

13.1.2 MERCK & CO., INC.219

TABLE 175 MERCK & CO., INC.: BUSINESS OVERVIEW219

FIGURE 53 MERCK & CO., INC.: COMPANY SNAPSHOT (2021)220

13.1.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH224

TABLE 176 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: BUSINESS OVERVIEW224

FIGURE 54 BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT (2021)225

13.1.4 ELANCO ANIMAL HEALTH INCORPORATED229

TABLE 177 ELANCO ANIMAL HEALTH INCORPORATED: BUSINESS OVERVIEW229

FIGURE 55 ELANCO ANIMAL HEALTH INCORPORATED: COMPANY SNAPSHOT (2021)230

13.1.5 VIRBAC234

TABLE 178 VIRBAC: BUSINESS OVERVIEW234

FIGURE 56 VIRBAC: COMPANY SNAPSHOT (2021)235

13.1.6 DECHRA PHARMACEUTICALS PLC238

TABLE 179 DECHRA PHARMACEUTICALS PLC: BUSINESS OVERVIEW238

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

FIGURE 57	DECHRA PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2021)	239
13.1.7	VETOQUINOL	243
TABLE 180	VETOQUINOL: BUSINESS OVERVIEW	243
FIGURE 58	VETOQUINOL: COMPANY SNAPSHOT (2021)	244
13.1.8	NEOGEN CORPORATION	247
TABLE 181	NEOGEN CORPORATION: BUSINESS OVERVIEW	247
FIGURE 59	NEOGEN CORPORATION: COMPANY SNAPSHOT (2021)	247
13.1.9	ORION GROUP	249
TABLE 182	ORION GROUP: BUSINESS OVERVIEW	249
FIGURE 60	ORION GROUP: COMPANY SNAPSHOT (2021)	250
13.1.10	ECO ANIMAL HEALTH GROUP PLC	252
TABLE 183	ECO ANIMAL HEALTH GROUP PLC: BUSINESS OVERVIEW	252
FIGURE 61	ECO ANIMAL HEALTH GROUP PLC: COMPANY SNAPSHOT (2021)	253
?		
13.2	OTHER PLAYERS	254
13.2.1	ZENEX ANIMAL HEALTH INDIA PRIVATE LIMITED	254
13.2.2	NORBROOK	255
13.2.3	CHANELLE PHARMA	256
13.2.4	HIPRA	257
13.2.5	CEVA SANTE ANIMALE	257
13.2.6	TIANJIN RINPU BIO-TECHNOLOGY CO., LTD.	259
13.2.7	KYORITSU SEIYAKU	260
13.2.8	ENDOVAC ANIMAL HEALTH	261
13.2.9	INDIAN IMMUNOLOGICALS LTD.	261
13.2.10	ASHISH LIFE SCIENCE PVT. LTD.	262
13.2.11	PHARMA PVT. LTD.	263
13.2.12	BIOGENESIS BAGO S.A.	264
13.2.13	INTAS PHARMACEUTICALS	265
13.2.14	BRILLIANT BIOPHARMA	266
13.2.15	VETINDIA PHARMACEUTICALS LIMITED	267
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.		
14	APPENDIX	268
14.1	INDUSTRY EXPERT INSIGHTS	268
14.2	DISCUSSION GUIDE	269
14.3	KNOWLEDGESTORE: MARKETSDMARKETS' SUBSCRIPTION PORTAL	273
14.4	CUSTOMIZATION OPTIONS	275
14.5	RELATED REPORTS	275
14.6	AUTHOR DETAILS	276

**Companion Animal Pharmaceuticals Market by Animal Type (Dogs, Cats, Horses),
Route of Administration (Oral, Injectable, Topical), Indication (Antibiotics,
Parasiticides), Distribution Channel (Veterinary Hospitals & Clinics) & Region - Global
Forecasts to 2027**

Market Report | 2023-03-22 | 268 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scottis-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scottis-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scottis-international.com

www.scottis-international.com

Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	2025-05-20
		Signature	<div></div>